# Phase 1 colonic cancer trials recruiting: 27 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 27 trials in phase 1 for colonic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 colonic cancer trials: 27 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/colonic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 27
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07897721 | A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors | Pfizer | Phase 1 | Not yet recruiting | Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic... | 268 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897721) |
| October 16, 2026 | NCT07878988 | This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic... | LTZ Therapeutics, Inc. | Phase 1 | Recruiting | Colorectal Cancer, Advanced/Metastatic Solid Tumor, Solid Tumor (Phase I), EPCAM, Colon Cancer | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878988) |
| September 4, 2026 | NCT07805369 | A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer | DEM BioPharma, Inc. | Phase 1 | Recruiting | Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805369) |
| July 15, 2026 | NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors | SHY Therapeutics | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705334) |
| March 9, 2026 | NCT07458347 | A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral... | Kestrel Therapeutics, Inc. | Phase 1 | Recruiting | KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant... | 545 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458347) |
| January 22, 2026 | NCT07361107 | Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC) | Northwell Health | Phase 1 | Recruiting | Colorectal (Colon or Rectal) Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07361107) |
| January 6, 2026 | NCT07321106 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With... | Cartography Biosciences | Phase 1 | Recruiting | Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC, Metastatic Colon Cancer, Colon... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07321106) |
| January 6, 2026 | NCT07318805 | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | Pfizer | Phase 1 | Recruiting | Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma... | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318805) |
| September 18, 2025 | NCT07179692 | CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Lung Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreas Cancer | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07179692) |
| August 17, 2025 | NCT07127874 | A Study of PHN-012 in Patients With Advanced Solid Tumors | Pheon Therapeutics | Phase 1 | Recruiting | Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer, Advanced Solid Tumors | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07127874) |
| July 25, 2025 | NCT07085091 | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | ALX Oncology Inc. | Phase 1 | Recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck... | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085091) |
| March 20, 2025 | NCT06885697 | Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | National Cancer Institute (NCI) | Phase 1 | Recruiting | Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06885697) |
| February 19, 2025 | NCT06835569 | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | Alterome Therapeutics, Inc. | Phase 1 | Recruiting | Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer), Advanced... | 448 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06835569) |
| November 4, 2024 | NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | Sponsor not shown (see the record) | Phase 1 | Recruiting | Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer... | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06673329) |
| July 18, 2024 | NCT06508307 | A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors | GONGCHU Biotechnology Co., Ltd | Phase 1 | Recruiting | Sarcoma, Cervical Cancer, Colon Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Hepatocellular Carcinoma... | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06508307) |
| May 13, 2024 | NCT06411691 | KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal... | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 | Recruiting | Colorectal Cancer, Pancreatic Cancer | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06411691) |
| November 13, 2023 | NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer, Lung Cancer, Esophagus Cancer, Cholangiocarcinoma, Pancreas... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06126406) |
| September 21, 2023 | NCT06043713 | T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer | Fred Hutchinson Cancer Center | Phase 1 | Recruiting | Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06043713) |
| September 15, 2023 | NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Revolution Medicines, Inc. | Phase 1 | Recruiting | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid... | 604 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06040541) |
| May 18, 2023 | NCT05865002 | A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) | Aurigene Discovery Technologies Limited | Phase 1 | Recruiting | Relapsed Malignant Solid Neoplasm | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05865002) |
| June 27, 2022 | NCT05433142 | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Xencor, Inc. | Phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma | 307 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05433142) |
| May 27, 2022 | NCT05394714 | A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study | Medigen Biotechnology Corporation | Phase 1 | Recruiting | Colon Cancer Stage I | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05394714) |
| March 16, 2022 | NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | Orano Med Theranostics, SAS | Phase 1 | Recruiting | Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer)... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05283330) |
| June 9, 2021 | NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | University of California, Irvine | Phase 1 | Recruiting | Colon Adenocarcinoma, Colorectal Cancer | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04920032) |
| April 13, 2021 | NCT04842812 | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 | Recruiting | Liver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer, Brain Tumor, Solid Tumor, Adult, PD1, CTLA4 | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04842812) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 2 |
| Medigen Biotechnology Corporation | 1 |
| University of California, Irvine | 1 |
| Kestrel Therapeutics, Inc. | 1 |
| RasCal Therapeutics, Inc. | 1 |
| Cartography Biosciences | 1 |
| ALX Oncology Inc. | 1 |
| GONGCHU Biotechnology Co., Ltd | 1 |
| Second Affiliated Hospital of Guangzhou Medical University | 1 |
| Fred Hutchinson Cancer Center | 1 |
| National Cancer Institute (NCI) | 1 |
| Northwell Health | 1 |
| [Xencor, Inc.](https://specstream.ai/data/clinical-trials/company/xencor-inc) | 1 |
| DEM BioPharma, Inc. | 1 |
| Pheon Therapeutics | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |
| Alterome Therapeutics, Inc. | 1 |
| Sichuan University | 1 |
| Aurigene Discovery Technologies Limited | 1 |
| SHY Therapeutics | 1 |
| Orano Med Theranostics, SAS | 1 |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 1 |
| LTZ Therapeutics, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 19 |
| China | 5 |
| Spain | 3 |
| France | 2 |
| Taiwan | 1 |
| Puerto Rico | 1 |
| Belgium | 1 |
| United Kingdom | 1 |
| Australia | 1 |
| South Korea | 1 |
| India | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Electronic equipment suppliers in the United States](https://specstream.ai/data/businesses/electronic-equipment-suppliers/united-states)
- [Suppliers and distributors in the United States](https://specstream.ai/data/businesses/suppliers-and-distributors/united-states)
- [German restaurants in the United States](https://specstream.ai/data/businesses/german-restaurants/united-states)
- [Welding supply stores in the United States](https://specstream.ai/data/businesses/welding-supply-stores/united-states)
- [IT service companies in the United States](https://specstream.ai/data/businesses/it-service-companies/united-states)
- [B2B marketing consultants in the United States](https://specstream.ai/data/businesses/b2b-marketing-consultants/united-states)
